Merck $95 million acquisition of cCam Biotherapeutics

29/8/2015

Public acquisition

Value:

$ 95 million

Status:

Completed

Date:

29/8/2015

Overview:

Merck has acquired cCam Biotherapeutics for an initial $95 million.
The deal also includes a potential $510 million in performance payments.
cCam Biotherapeutics is an Israeli biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies.

Sam Duke - Editor

Jurisdiction:

Israel

Deal type:

Public acquisition

Practice area:

M&A

Industry sectors:

Healthcare
Pharmaceuticals and life sciences

Firms:

Arnon, Tadmor-Levy

Party: OrbiMed (Seller, Shareholder)

Lawyer: Barry Levenfeld

Horn & Co

Party: cCam Biotherapeutics (Target)

Lawyer: Yuval Horn

Meitar | Law Offices

Party: Merck (Acquirer)

Lawyer: Clifford Felig

WilmerHale

Party: cCam Biotherapeutics (Target)

Related deals